The company's revenue increased $120.0 million to $879.0million in FY2018.
Showing 25 of 1905
Shares of the health sciences company soar sharply in both Canada and New York
The company aims to produce high purity alumina (HPA) from its kaolin feedstock.
Ed Rayner is an investment director for major shareholder Arix Bioscience Plc (LSE:ARIX).
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
The milk will be promoted on China’s JiaJia TV shopping channel which has 385 million viewers.
The company sells clinically validated anti-ageing products for hair, skin and body.
The company recommenced trading today up 13.3% to 3.4 cents per share.
The company aims to release its first medicinal cannabis products in FY2019.
Cellmid can now apply to the US FDA and European EMA for Orphan Drug Designation for CAB102.
The company has bounced off its July low of 88 cents to be trading at 99 cents today.
The licence opens up potential international markets for its cannabis-based medicines.
Funds raised in the IPO will be used to acquire more podiatry and physio businesses.
NanoCelle™ is a mouth spray delivery system targeting cannabis-based medicines.
The company’s chief executive Nicholas Simms will speak at the first ASX Small and Mid-Cap Conference in Sydney on Thursday.
The partnership provides access to the rapidly growing German market.
The test work indicates that the feedstock can potentially be further purified for higher-grade products.
The company will move onto phase II studies after this phase is complete.
The deal secures equity funding, a new loan facility and a gateway to the China market.
Auscann has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.
Cynata can produce enough stem cells that a mesenchymal stem cell product could be produced with just one donor.
Store presence is expected to increase sales, building on the successful online launch.
The company is a vertically integrated player thanks to early-mover partnerships.
Shares in the company have more than tripled over the past 12 months.
The positive study findings will allow FYI to begin formal permitting for its proposed high purity alumina operation.